Literature DB >> 8139024

Activation of cerebral cytokine gene expression and its correlation with onset of reactive astrocyte and acute-phase response gene expression in scrapie.

I L Campbell1, M Eddleston, P Kemper, M B Oldstone, M V Hobbs.   

Abstract

The pathogenesis of scrapie, a transmissible subacute spongiform encephalopathy, is unclear. However, certain aspects of the known cellular and molecular neuropathology in scrapie led us to hypothesize that cytokines could mediate cerebral pathological changes in this neurodegenerative disease. Therefore, expression of multiple cytokine genes in the brain and peripheral organs of scrapie-infected mice was examined. Late in the course of scrapie, expression of tumor necrosis factor alpha (TNF-alpha), interleukin-1 alpha (IL-1 alpha), and IL-1 beta mRNA was markedly increased in the brain but not the spleen, kidneys, or liver. In time course studies, scrapie-infected mice exhibited increased cerebral expression of the TNF-alpha, IL-1 alpha, and IL-1 beta mRNAs by week 15 postinoculation--a time point that coincided with the onset of clinical symptoms. Thereafter, the levels of these cytokine transcripts increased progressively to the terminal stages of of the disease (week 25). To determine the relationship of the increased cerebral expression of the cytokine mRNAs to the development of pathological changes in scrapie, we examined the expression of the glial fibrillary acidic protein gene (a marker for astrocytosis) and the murine acute-phase response gene homologous to the alpha 1-antichymotrypsin gene (designated EB22/5.3). Markedly increased expression of both the glial fibrillary acidic protein and EB22/5.3 mRNAs was observed in the brain but not the peripheral organs of scrapie-infected mice. The increased expression of both these gene products also occurred at week 15 of infection and, thereafter, increased progressively to the terminal stages of the disease. Therefore, infection of mice with scrapie resulted in significant increases in the expression of the TNF-alpha, IL-1 alpha, and IL-1 beta gene products, whose pattern correlated with the onset and development of molecular and clinical pathological changes. Since scrapie is known not to evoke an immune response, the present findings strongly suggest the existence of a localized cerebral host response to the agent during which proinflammatory cytokines could be key pathogenic mediators.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8139024      PMCID: PMC236715     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor.

Authors:  K W Selmaj; M Farooq; W T Norton; C S Raine; C F Brosnan
Journal:  J Immunol       Date:  1990-01-01       Impact factor: 5.422

Review 2.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

3.  Changes in brain gene expression shared by scrapie and Alzheimer disease.

Authors:  J R Duguid; C W Bohmont; N G Liu; W W Tourtellotte
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

4.  Nucleotide sequence of a full-length cDNA for mouse cytoskeletal beta-actin mRNA.

Authors:  K Tokunaga; H Taniguchi; K Yoda; M Shimizu; S Sakiyama
Journal:  Nucleic Acids Res       Date:  1986-03-25       Impact factor: 16.971

5.  Scrapie infection diminishes spines and increases varicosities of dendrites in hamsters: a quantitative Golgi analysis.

Authors:  R N Hogan; J R Baringer; S B Prusiner
Journal:  J Neuropathol Exp Neurol       Date:  1987-07       Impact factor: 3.685

Review 6.  Cytokines: an expanding network of immuno-inflammatory hormones.

Authors:  L C Harrison; I L Campbell
Journal:  Mol Endocrinol       Date:  1988-12

7.  Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus.

Authors:  A P Lieberman; P M Pitha; H S Shin; M L Shin
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

8.  Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularization.

Authors:  D Giulian; J Woodward; D G Young; J F Krebs; L B Lachman
Journal:  J Neurosci       Date:  1988-07       Impact factor: 6.167

9.  Interleukin-1 stimulation of astroglial proliferation after brain injury.

Authors:  D Giulian; L B Lachman
Journal:  Science       Date:  1985-04-26       Impact factor: 47.728

10.  Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.

Authors:  W S Griffin; L C Stanley; C Ling; L White; V MacLeod; L J Perrot; C L White; C Araoz
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

View more
  51 in total

1.  Identification of upregulated genes in scrapie-infected brain tissue.

Authors:  C Riemer; I Queck; D Simon; R Kurth; M Baier
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Astrocyte-specific expression of hamster prion protein (PrP) renders PrP knockout mice susceptible to hamster scrapie.

Authors:  A J Raeber; R E Race; S Brandner; S A Priola; A Sailer; R A Bessen; L Mucke; J Manson; A Aguzzi; M B Oldstone; C Weissmann; B Chesebro
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

3.  Upregulation of the genes encoding lysosomal hydrolases, a perforin-like protein, and peroxidases in the brains of mice affected with an experimental prion disease.

Authors:  J Kopacek; S Sakaguchi; K Shigematsu; N Nishida; R Atarashi; R Nakaoke; R Moriuchi; M Niwa; S Katamine
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  IL-1 family members as candidate genes modulating scrapie susceptibility in sheep: localization, partial characterization, and expression.

Authors:  Ane Marcos-Carcavilla; Jorge H Calvo; Carmen González; Katayoun Moazami-Goudarzi; Pascal Laurent; Maud Bertaud; Hélène Hayes; Anne E Beattie; Carmen Serrano; Jaber Lyahyai; Inmaculada Martín-Burriel; Estefânia Alves; Pilar Zaragoza; Juan J Badiola; Magdalena Serrano
Journal:  Mamm Genome       Date:  2007-01-22       Impact factor: 2.957

Review 5.  Microglia in prion diseases.

Authors:  Adriano Aguzzi; Caihong Zhu
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

6.  The bacteriostatic protein lipocalin 2 is induced in the central nervous system of mice with west Nile virus encephalitis.

Authors:  Aline L Noçon; Jacque P K Ip; Rachael Terry; Sue Ling Lim; Daniel R Getts; Marcus Müller; Markus J Hofer; Nicholas J C King; Iain L Campbell
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

7.  Identification of chemoattractive factors involved in the migration of bone marrow-derived mesenchymal stem cells to brain lesions caused by prions.

Authors:  Chang-Hyun Song; Osamu Honmou; Hidefumi Furuoka; Motohiro Horiuchi
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

8.  Borna disease virus accelerates inflammation and disease associated with transgenic expression of interleukin-12 in the central nervous system.

Authors:  Susanna Freude; Jürgen Hausmann; Markus Hofer; Ngan Pham-Mitchell; Iain L Campbell; Peter Staeheli; Axel Pagenstecher
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

9.  Effect of transplantation of bone marrow-derived mesenchymal stem cells on mice infected with prions.

Authors:  Chang-Hyun Song; Osamu Honmou; Natsuo Ohsawa; Kiminori Nakamura; Hirofumi Hamada; Hidefumi Furuoka; Rie Hasebe; Motohiro Horiuchi
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

10.  Abnormal activation of microglia accompanied with disrupted CX3CR1/CX3CL1 pathway in the brains of the hamsters infected with scrapie agent 263K.

Authors:  Wu-Ling Xie; Qi Shi; Jin Zhang; Bao-Yun Zhang; Han-Shi Gong; Yan Guo; Shao-Bin Wang; Yin Xu; Ke Wang; Cao Chen; Yong Liu; Xiao-Ping Dong
Journal:  J Mol Neurosci       Date:  2013-03-24       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.